World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
45084
World Ranking
14832
National Ranking
7496

Overview

Shirish M. Gadgeel is affiliated with the University of Michigan-Ann Arbor in the United States. Their research primarily focuses on medicine, with a strong emphasis on oncology and pulmonary and respiratory medicine. Additional subfields of study include molecular biology, cancer research, and radiology, nuclear medicine, and imaging.

The scientist's research covers several main topics, notably lung cancer treatments and mutations, cancer immunotherapy and biomarkers, lung cancer research studies, cancer genomics and diagnostics, lung cancer diagnosis and treatment, colorectal cancer treatments and studies, and HER2/EGFR in cancer research.

Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Clinical Lung Cancer
  • Annals of Oncology

Notable recent papers authored by Shirish M. Gadgeel include:

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer (2020, Journal of Clinical Oncology)
  • Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation (2022, New England Journal of Medicine, authored by Pasi A. Jänne)
  • Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study (2020, Annals of Oncology, authored by Tony Mok)
  • Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study (2023, Journal of Clinical Oncology, authored by Marina Chiara Garassino)
  • Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study (2021, The Lancet Oncology, authored by Justin F. Gainor)

The scientist has collaborated extensively with several frequent co-authors, including:

  • Enriqueta Felip
  • Alexander I. Spira
  • Balázs Halmos
  • Sai-Hong Ignatius Ou
  • Tony Mok

In addition to articles, Shirish M. Gadgeel has contributed to book publications, including a title published by Cambridge University Press in 2023 called Targeting Oncogenic Driver Mutations in Lung Cancer.

Best Publications

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study

    Shirish M. Gadgeel;Leena Gandhi;Gregory J. Riely;Alberto A. Chiappori

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee

  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Benjamin J. Solomon;Benjamin Besse;Benjamin Besse;Todd M. Bauer;Enriqueta Felip

  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

    Alice T Shaw;Leena Gandhi;Shirish Gadgeel;Gregory J Riely

  • Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

    Patricia M. LoRusso;Alex A. Adjei;Mary Varterasian;Shirish Gadgeel

  • Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.

    T. Mok;D.R. Camidge;S.M. Gadgeel;R. Rosell

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean Charles Soria;Enriqueta Felip;Manuel Cobo;Shun Lu

  • Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

    D. Ross Camidge;Rafal Dziadziuszko;Solange Peters;Tony Mok

  • The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions

    Louis A. Penner;John F. Dovidio;Richard Gonzalez;Terrance L. Albrecht

  • Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer

    John V. Heymach;Bruce E. Johnson;Diane Prager;Edit Csada

  • Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

    Justin F. Gainor;Giuseppe Curigliano;Dong Wan Kim;Dae Ho Lee

  • A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

    Eric B. Haura;Alejandro D. Ricart;Timothy G. Larson;Philip J. Stella

  • Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer

    J. Gainor;L. Dardaei;S. Yoda;L. Friboulet

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean-Charles Soria;Soria Jean-Charles;Enriqueta Felip;Felip Enriqueta

Frequent Co-Authors

Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
D. Ross Camidge
D. Ross Camidge University of Colorado Anschutz Medical Campus
Alice T. Shaw
Alice T. Shaw Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Ann G. Schwartz
Ann G. Schwartz Wayne State University
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Edward B. Garon
Edward B. Garon University of California, Los Angeles
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to various online degree options and related healthcare fields. Many students consider healthcare administration programs to understand the business and organizational side of healthcare. These programs equip graduates for leadership roles and can be completed online, offering valuable flexibility.

For registered nurses seeking advancement, numerous rn to fnp programs allow working nurses to transition smoothly into Family Nurse Practitioner roles. These bridge programs can also be pursued online, supporting career growth while balancing current job responsibilities.

Those interested in preventative care and wellness may explore the best online nutrition degree programs. These degrees provide foundational knowledge in nutrition science and can lead to diverse opportunities in clinical, community, or corporate settings.

When researching graduate studies, ensure your program holds recognized accreditation such as cahme accreditation, which assures high-quality standards for health administration master’s degrees. Choosing accredited online programs can enhance your credentials and expand your professional options within the healthcare sector.

Best Scientists Citing Shirish M. Gadgeel

Trending Scientists

Recently Published Articles